🔗 Share this article

As the United States undertakes sweeping revisions to its vaccine schedules, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by casting doubt on Covid vaccinations during the global health crisis and has focused upon possible fatalities following COVID-19 vaccination in her brief position at the Food and Drug Administration.

Proposed Overhauls to Childhood Immunization Schedule

Public health authorities had intended to reveal major changes to the pediatric immunization program recently, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US out of alignment with much of the global community with insufficient data for improved outcomes. The planned update has been delayed until the next year.

In place of the director of the vaccine center, Høeg is listed to speak at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to lead the center this year.

A Shift at the FDA

Høeg's temporary position might represent a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific pediatric immunization guidelines in the US to become more similar to Denmark, a nation with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccination policy – traditionally the domain of Dr. Prasad, head of the FDA’s vaccine center – instead of medication approval.

Concerns Over Background

Dr. Høeg has no obvious track record in medication creation, approval processes or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a large organization. She is not an expert in industry regulation.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the research of medication creation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that former directors who headed the center have had.”

CDER has an vast portfolio at the FDA, Woodcock stated.

“The public just zeroes in on the innovative therapies, but the generic program authorizes thousands of generic medications. There’s a biologic copycat branch, OTC medication office and so forth, and each of these need to be managed,” Dr. Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a major leadership aspect to the position, which manages more than 5,000 employees. “It is a huge administrative position, if you perform it correctly,” the former official said.

Agency Reaction and Disputed Programs

In response to inquiries about Dr. Høeg's credentials and whether this assignment indicates more teamwork among regulatory chiefs on vaccines, a spokesperson responded that the “inquiries stem from flawed presumptions”.

“Her experience is consistent with the duties of her position,” the official explained, pointing to the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial rapid medication authorization process that apparently troubled her former heads. “By what process are these drugs being chosen for this fast-track system? Who is making the choices?” Dr. Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

In general, he remarked, “the FDA appears to be shifting towards more relaxed regulations of pharmaceuticals, except for vaccines.”

Public Past Work on Vaccines

Concerning vaccines, Dr. Høeg has a clearer, if problematic, past, critics said. She authored a study using unverified public submissions to assess the rate of myocarditis after Covid immunization. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are riskier than they are.

Among her “desired changes” for the new administration encompassed changing regulations for new vaccines and ending “non-essential” immunizations, she stated after the election on a podcast. At the agency, Dr. Høeg has allegedly suggested excluding young men from getting COVID-19 vaccinations.

“She is an thorough true believer who commences with her conclusions and works backwards to retrofit the data in a very deceptive, dishonest fashion,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with fellow contrarians, {like|